Antibody Solution Kit for Separation and Characterization of Monoclonal Antibodies and Antibody Fragments
P/N |
Phase |
Dimension |
Pore Size |
MABKIT-0000 |
Zenix™ SEC-300 |
4.6 × 300 mm |
300 Å |
Antibodix™ WCX-NP5 |
4.6 × 250 mm |
Non-porous |
Monoclonal antibodies have been increasingly becoming drug candidates for disease therapeutics. Due to the molecular complexity of monoclonal antibodies, the characterization remains a challenge and required step throughout the development and manufacturing process. In order to determine the efficacy of the molecules, aggregation, heterogeneity such as charge variants, C-terminal lysine processing, deamidation, glycosylation, MAbs must be screened for their structural and biological changes.
In the kit, the Zenix™-300 size exclusion chromatographic (SEC) column is designed for high efficiency and resolution separation of monoclonal antibody monomers, aggregates, fragments such as heavy/light, fab/fc and f(ab')2 fragments. With volatile mobile phase systems, Zenix-300 is able to separate MAb fragments, which can be analyzed by on-line mass spectrometry. Molecular weight information of MAb fragments is then obtained with SEC-LC/MS work flow. The antibody solution kit provides AntibodixTM NP5 weak cation exchange column to separate the charge variants. Multiple mobile phase systems were investigated for optimum charge variant separation.
With Zenix™-300 SEC and Antibodix NP5, antibody solution kit offers a complete set of tools for monoclonal antibody analysis.
bio-equip.cn
Profile
Sepax Technologies, Inc., a privately held company, was founded in Delaware, USA in November 2002. It develops and manufactures HPLC consumables, bulk media, and equipment in liquid chromatography for chemical and biological separations. It is a fast growing technology company and owns patents, proprietary technologies and know-how. Sepax has emerged as a leader in the biological separation industry in the global market.
Business strategies
Sepax Technologies, Inc. develops innovative HPLC consumables, bulk media, and instruments to solve separation challenges in the global market. We provide solution-based products by closely working with our customer scientists in pharmaceuticals, biopharmaceuticals, research institutes and government labs. Our strong technical team develops various methods with our customers to analyze complex biological molecules. As a leader in the biological separation industry, we constantly develop the best bio-separation technologies and products for our global customers. We have reached a competitive position globally in fast growing regions.
Vision Statement
To become a technology leader in the biological separation industry in the global market and provide solution based products and services for our customers.
Operation
Sepax Technologies, Inc.
Our company headquarter in Delaware is located in Delaware Technology Park with facilities of 15,000 ft2 dedicated to the development of separation resin technologies and instrumentation, production of HPLC resins, columns and CE consumables. It is also the marketing and sales center for our US and global markets.
Sales
Domestic
Audrey Fisher
Field Sales Account Manager
(Northern CA areas, UT, CO, OR)
Direct Phone: 925-324-5223
Email: afisher@sepax-tech.com
Kathleen Falls
West Coast Regional Manager
(All other CA areas, WA, TX, AZ, NM, MI)
Direct Phone: 323-228-0004
Email: kfalls@sepax-tech.com
Michael Hunnewell
Field Sales Account Manager
(MA, RI, NH, CT, NY)
Direct Phone: 302-650-3955
Email: mhunnewell@sepax-tech.com
Colleen Callahan
Midwest Account Manager
(WI, IL, IN, OH, MO)
Direct Phone: 302-366-1101, ext 106
Cell Phone: 302-339-8747
Email: ccallahan@sepax-tech.com
All other areas, please contact
Helen Gu
Vice President, Sales
Direct phone: 302-650-3909
Email: hgu@sepax-tech.com
International
Tingting Wu
Executive Account Manager/Marketing
Phone: 302-366-1101, ext 115
Email: twu@sepax-tech.com